Author: admin

DelveInsight’s “Recurrent Respiratory Papillomatosis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Recurrent Respiratory Papillomatosis, historical and forecasted epidemiology as well as the Recurrent Respiratory Papillomatosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Recurrent Respiratory Papillomatosis, offering comprehensive insights into the Recurrent Respiratory Papillomatosis revenue trends, prevalence, and treatment landscape. The report delves into key Recurrent Respiratory Papillomatosis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Recurrent Respiratory Papillomatosis therapies. Additionally, we cover the landscape of Recurrent Respiratory Papillomatosis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Recurrent Respiratory Papillomatosis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Recurrent Respiratory Papillomatosis space.

To Know in detail about the Recurrent Respiratory Papillomatosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Recurrent Respiratory Papillomatosis Market Forecast

Some of the key facts of the Recurrent Respiratory Papillomatosis Market Report:

• The Recurrent Respiratory Papillomatosis market size was valued ~USD 10.26 million in 2023 and is anticipated to grow with a significant CAGR of 39.9% during the study period (2020-2034)

• In February 2025, INOVIO (NASDAQ: INO), a biotechnology company focused on developing DNA medicines for HPV-related conditions, cancer, and infectious diseases, announced that peer-reviewed results from its Phase 1/2 trial of INO-3107 for recurrent respiratory papillomatosis (RRP) have been published in Nature Communications. The study, titled DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107, revealed that INO-3107 stimulated new T cell populations in the blood that migrated to the airway and papilloma tissues, correlating with fewer surgeries post-treatment. Of the 32 patients enrolled, 26 (81%) needed fewer surgical interventions after treatment compared to the year before. The therapy was also well tolerated. INOVIO intends to submit a Biologics License Application (BLA) for INO-3107 by mid-2025 and will seek rolling submission and priority review through the FDA’s accelerated approval pathway. If approved, INO-3107 would become the first DNA-based medicine approved for any condition in the U.S.

• In December 2024, Precigen, Inc. announced that it has completed the submission of its biologics license application (BLA) to the FDA for PRGN-2012 (zopapogene imadenovec†) as a treatment for adult recurrent respiratory papillomatosis (RRP).

• In August 2024, Precigen announced a strategic shift to concentrate on the potential commercialization of PRGN-2012. As part of this realignment, the company will reduce its workforce by 20% and halt all preclinical programs. This decision highlights Precigen’s dedication to advancing PRGN-2012 and reallocating resources to enhance its commercial potential.

• The EU4 and the UK represented about 16% of the 7MM market size, with the RRP market valued at approximately USD 1.66 million in 2023.

• In 2023, Germany had the largest market size for RRP among the EU countries, reaching nearly USD 0.45 million, whereas Spain had the smallest market size, approximately USD 0.25 million.

• The overall market size of RRP is expected to increase during the forecast period, driven by the anticipated introduction of emerging therapies such as INO-3107, PRGN-2012, and others.

• Key Recurrent Respiratory Papillomatosis Companies: Precigen, Inc., Inovio Pharmaceuticals, and others

• Key Recurrent Respiratory Papillomatosis Therapies: PRGN-2012, INO-3107, and others

• The Recurrent Respiratory Papillomatosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Recurrent Respiratory Papillomatosis pipeline products will significantly revolutionize the Recurrent Respiratory Papillomatosis market dynamics.

• The total number of diagnosed prevalent cases of RRP in the US was approximately 16,980 in 2023 and is expected to rise during the forecast period.

• According to DelveInsight’s estimates, the US has the highest number of diagnosed prevalent cases of RRP among the 7MM, followed by the EU4 and the UK, with Japan contributing to 24% and 10% of all RRP cases, respectively.

• In 2023, Japan reported the highest number of RRP cases in adults aged 18 and older (~2,400), followed by adolescents aged 9-17 years (~50). The fewest cases were observed in children aged 0-8 years, with a total of approximately 25.

• In 2023, the EU4 and the UK reported a total of approximately 6,240 diagnosed prevalent cases of RRP, with around 5,740 cases linked to HPV 6 and/or HPV 11, and about 500 cases associated with other high-risk subtypes such as HPV-16, 18, 31, 33, and 39. The large number of cases related to HPV 6 and 11 highlights the dominant role these strains play in RRP, as they are the primary causative agents.

• In 2023, Germany reported the highest number of diagnosed prevalent RRP cases among the EU4 and the UK, with nearly 1,684 cases. France followed with around 1,370 cases, Italy had approximately 1,220, the UK reported about 1,022, and Spain had the lowest with roughly 944 cases. This distribution underscores the differing disease burden across European countries.

Recurrent Respiratory Papillomatosis Overview

Recurrent Respiratory Papillomatosis (RRP) is a rare condition characterized by the growth of benign tumors, called papillomas, in the airways, primarily affecting the larynx, trachea, and bronchi. These growths are caused by infection with the human papillomavirus (HPV), particularly types 6 and 11. RRP can lead to airway obstruction, hoarseness, breathing difficulties, and recurrent infections. The condition is chronic, often requiring repeated surgical interventions to remove the papillomas. It can occur in both children (juvenile-onset RRP) and adults (adult-onset RRP), with varying severity and progression.

Get a Free sample for the Recurrent Respiratory Papillomatosis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/recurrent-respiratory-papillomatosis-market

Recurrent Respiratory Papillomatosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Recurrent Respiratory Papillomatosis Epidemiology Segmentation:

The Recurrent Respiratory Papillomatosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Recurrent Respiratory Papillomatosis

• Prevalent Cases of Recurrent Respiratory Papillomatosis by severity

• Gender-specific Prevalence of Recurrent Respiratory Papillomatosis

• Diagnosed Cases of Episodic and Chronic Recurrent Respiratory Papillomatosis

Download the report to understand which factors are driving Recurrent Respiratory Papillomatosis epidemiology trends @ Recurrent Respiratory Papillomatosis Epidemiology Forecast

Recurrent Respiratory Papillomatosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Recurrent Respiratory Papillomatosis market or expected to get launched during the study period. The analysis covers Recurrent Respiratory Papillomatosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Recurrent Respiratory Papillomatosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Recurrent Respiratory Papillomatosis Therapies and Key Companies

• PRGN-2012: Precigen, Inc.

• INO-3107: Inovio Pharmaceuticals

Discover more about therapies set to grab major Recurrent Respiratory Papillomatosis market share @ Recurrent Respiratory Papillomatosis Treatment Landscape

Recurrent Respiratory Papillomatosis Market Drivers

• Increasing Incidence of HPV Infections

• Advancements in Surgical and Therapeutic Options

• Rising Awareness and Early Diagnosis

• Improved Treatment Modalities

• Research and Development Investments

Recurrent Respiratory Papillomatosis Market Barriers

• Limited Awareness and Diagnosis

• Lack of Cure

• High Treatment Costs

• Fragmented Treatment Landscape

• Limited Availability of Effective Therapies

• Challenges in HPV Vaccination Implementation

Scope of the Recurrent Respiratory Papillomatosis Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Recurrent Respiratory Papillomatosis Companies: Precigen, Inc., Inovio Pharmaceuticals, and others

• Key Recurrent Respiratory Papillomatosis Therapies: PRGN-2012, INO-3107, and others

• Recurrent Respiratory Papillomatosis Therapeutic Assessment: Recurrent Respiratory Papillomatosis current marketed and Recurrent Respiratory Papillomatosis emerging therapies

• Recurrent Respiratory Papillomatosis Market Dynamics: Recurrent Respiratory Papillomatosis market drivers and Recurrent Respiratory Papillomatosis market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Recurrent Respiratory Papillomatosis Unmet Needs, KOL’s views, Analyst’s views, Recurrent Respiratory Papillomatosis Market Access and Reimbursement

To know more about Recurrent Respiratory Papillomatosis companies working in the treatment market, visit @ Recurrent Respiratory Papillomatosis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Recurrent Respiratory Papillomatosis Market Report Introduction

2. Executive Summary for Recurrent Respiratory Papillomatosis

3. SWOT analysis of Recurrent Respiratory Papillomatosis

4. Recurrent Respiratory Papillomatosis Patient Share (%) Overview at a Glance

5. Recurrent Respiratory Papillomatosis Market Overview at a Glance

6. Recurrent Respiratory Papillomatosis Disease Background and Overview

7. Recurrent Respiratory Papillomatosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Recurrent Respiratory Papillomatosis

9. Recurrent Respiratory Papillomatosis Current Treatment and Medical Practices

10. Recurrent Respiratory Papillomatosis Unmet Needs

11. Recurrent Respiratory Papillomatosis Emerging Therapies

12. Recurrent Respiratory Papillomatosis Market Outlook

13. Country-Wise Recurrent Respiratory Papillomatosis Market Analysis (2020–2034)

14. Recurrent Respiratory Papillomatosis Market Access and Reimbursement of Therapies

15. Recurrent Respiratory Papillomatosis Market Drivers

16. Recurrent Respiratory Papillomatosis Market Barriers

17. Recurrent Respiratory Papillomatosis Appendix

18. Recurrent Respiratory Papillomatosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Recurrent Respiratory Papillomatosis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Precigen, Inovio Pharma

DelveInsight’s “Pulmonary Arterial Hypertension Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Pulmonary Arterial Hypertension, historical and forecasted epidemiology as well as the Pulmonary Arterial Hypertension market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Pulmonary Arterial Hypertension market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pulmonary Arterial Hypertension pipeline products will significantly revolutionize the Pulmonary Arterial Hypertension market dynamics.

To Know in detail about the Pulmonary Arterial Hypertension market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pulmonary Arterial Hypertension Market Forecast

Some of the key facts of the Pulmonary Arterial Hypertension Market Report:

• The Pulmonary Arterial Hypertension market size was valued approximately USD 4,949 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In March 2025, Merck (NYSE: MRK), also known as MSD outside the U.S. and Canada, has shared initial results from its Phase 3 ZENITH trial evaluating WINREVAIR™ (sotatercept-csrk) versus placebo in adults with pulmonary arterial hypertension (PAH, Group 1 PH), classified as WHO functional class III or IV and at high risk of mortality, despite receiving the maximum tolerated background PAH therapy. With a median follow-up of 10.6 months (range: 0.3–26.1), WINREVAIR significantly reduced the relative risk of major morbidity and mortality events—including all-cause death, lung transplantation, or PAH-related hospitalization (≥24 hours)—by 76% (HR=0.24 [95% CI, 0.13–0.43]; p

• In January 2025, Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced preliminary findings from its Phase 3 ZENITH trial assessing WINREVAIR™ (sotatercept-csrk) against placebo in adults with pulmonary arterial hypertension (PAH, Group 1 PH), specifically those categorized as WHO functional class III or IV and considered at high risk of mortality despite being on optimized background PAH treatment. Over a median follow-up period of 10.6 months (range: 0.3–26.1), WINREVAIR demonstrated a 76% reduction in the relative risk of major morbidity and mortality events—defined as all-cause death, lung transplant, or PAH-related hospitalization lasting 24 hours or more—compared to placebo (HR=0.24 [95% CI, 0.13–0.43]; p

• In October 2024, Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company focused on developing protein kinase inhibitors to address cardiopulmonary and neurodegenerative diseases via Abelson Tyrosine Kinase inhibition, has announced the closing of a $110 million private placement. This funding, generated through the sale of common stock and accompanying warrants, could potentially reach $275 million upon full cash exercise of the warrants, prior to deducting placement agent fees and expenses. The proceeds will support the execution of the Phase 2b ‘702’ trial for pulmonary arterial hypertension (PAH) and general corporate activities.

• In July 2024, Aerovate Therapeutics is reducing its workforce by 78%, following the Phase IIb trial failure of its pulmonary arterial hypertension (PAH) drug, AV-101. The Massachusetts-based biotech disclosed the layoffs in an SEC filing, estimating related costs at approximately $5.6 million

• In 2022, the Pulmonary Arterial Hypertension treatment market in the US was valued at around USD 3,898.5 million, and it is expected to grow due to rising awareness of the condition and the introduction of new therapies.

• In 2022, the Pulmonary Arterial Hypertension market size in EU4 and the UK was estimated at approximately USD 816.4 million, accounting for nearly 16% of the total market revenue across the 7MM.

• As per DelveInsight’s estimates, Germany had the largest Pulmonary Arterial Hypertension drugs market in EU4 and the UK, reaching around USD 210.3 million in 2022, followed by France at approximately USD 207.9 million. In contrast, Spain had the smallest market in 2023.

• The evolving pipeline for pulmonary arterial hypertension (PAH) includes various treatments such as Sotatercept (MK-7962) from Merck, ralinepag by United Therapeutics, RT234 (vardenafil inhalation powder) developed by Respira Therapeutics, seralutinib (GB002) from Gossamer Bio, YUTREPIA (an inhaled dry powder formulation of treprostinil) created by Liquidia Technologies, and TNX-201 by Tenax Therapeutics. These treatments are anticipated to be introduced and made available throughout the forecast period from 2023 to 2032.

• In 2022, the collective number of existing cases of pulmonary arterial hypertension (PAH) in the 7MM (Seven Major Markets) was estimated to be around 88,100 cases. Over the study duration (2019─2032), it is anticipated that these cases will show a gradual increase, projected to grow at a Compound Annual Growth Rate (CAGR) of 0.4% by 2032

• In the European Union Four (EU4) and the United Kingdom (UK) combined, there were an estimated 19,720 diagnosed cases of pulmonary arterial hypertension (PAH) in 2022. It is anticipated that these diagnosed cases will experience an increase throughout the study period from 2019 to 2032.

• In 2022, Japan recorded an estimated 204 cases of class I, 1,143 occurrences of class II, 901 cases of class III, and 136 cases of class IV pulmonary arterial hypertension (PAH). It is anticipated that these figures will show a decline over the study period from 2019 to 2032.

• Key Pulmonary Arterial Hypertension Companies: Aerovate Therapeutics, Novartis, Keros Therapeutics, Vigonvita Life Sciences, Insmed Incorporated, Chugai Pharmaceutical, Merck Sharp & Dohme, Janssen Pharmaceutical, Actelion, Gossamer Bio, Lung Biotechnology PBC, United Therapeutics, Gilead Science, Acceleron Pharma, Eiger BioPharmaceuticals, AstraZeneca, and others

• Key Pulmonary Arterial Hypertension Therapies: AV-101, LTP001, KER-012, TPN171H, Treprostinil Palmitil, Satralizumab (Genetical Recombination), Sotatercept, Macitentan, ACT-293987, GB002 (seralutinib), Parenteral Treprostinil, Ralinepag, Selonsertib, Sotatercept, ubenimex, Olaparib, and others

• The Pulmonary Arterial Hypertension epidemiology based on gender analyzed that females are more affected with Pulmonary Arterial Hypertension than males

• The Pulmonary Arterial Hypertension market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pulmonary Arterial Hypertension pipeline products will significantly revolutionize the Pulmonary Arterial Hypertension market dynamics.

Pulmonary Arterial Hypertension Overview

When measured by right heart catheterization, pulmonary hypertension (PH) is defined as mean pulmonary artery pressure greater than 25 mm Hg at rest or greater than 30 mm Hg during activity. PH has been classified into five groups by the World Health Organization (WHO) on the basis of shared pathophysiology, clinical presentation, and available treatments.

Get a Free sample for the Pulmonary Arterial Hypertension Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-market

Pulmonary Arterial Hypertension Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Pulmonary Arterial Hypertension Epidemiology Segmentation:

The Pulmonary Arterial Hypertension market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Pulmonary Arterial Hypertension

• Prevalent Cases of Pulmonary Arterial Hypertension by severity

• Gender-specific Prevalence of Pulmonary Arterial Hypertension

• Diagnosed Cases of Episodic and Chronic Pulmonary Arterial Hypertension

Download the report to understand which factors are driving Pulmonary Arterial Hypertension epidemiology trends @ Pulmonary Arterial Hypertension Epidemiology Forecast

Pulmonary Arterial Hypertension Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pulmonary Arterial Hypertension market or expected to get launched during the study period. The analysis covers Pulmonary Arterial Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Pulmonary Arterial Hypertension Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Pulmonary Arterial Hypertension Therapies and Key Companies

• AV-101: Aerovate Therapeutics

• LTP001: Novartis

• KER-012: Keros Therapeutics

• TPN171H: Vigonvita Life Sciences

• Treprostinil Palmitil: Insmed Incorporated

• Satralizumab (Genetical Recombination): Chugai Pharmaceutical

• Sotatercept: Merck Sharp & Dohme

• Macitentan: Janssen Pharmaceutical

• ACT-293987: Actelion

• GB002 (seralutinib): Gossamer Bio

• Parenteral Treprostinil: Lung Biotechnology PBC

• Ralinepag: United Therapeutics

• Selonsertib: Gilead Sciences

• Sotatercept: Acceleron Pharma

• ubenimex: Eiger BioPharmaceuticals

• Olaparib: AstraZeneca

Discover more about therapies set to grab major Pulmonary Arterial Hypertension market share @ Pulmonary Arterial Hypertension Treatment Landscape

Pulmonary Arterial Hypertension Market Strengths

• Better understanding of disease pathophysiology and genetics has improved diagnosis and treatment, reducing mortality

• There have been significant developments in the treatment regime leading to the approval of novel therapies and more defined treatment guidelines

Pulmonary Arterial Hypertension Market Opportunities

• Further research on diagnostic and prognostic blood biomarkers in asymptomatic or specific at-risk populations to improve diagnosis and develop novel treatment options

• The increasing prevalence of PAH, along with government support for the development of orphan drugs, provide companies with an excellent opportunity to invest in the PAH market

Scope of the Pulmonary Arterial Hypertension Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Pulmonary Arterial Hypertension Companies: Aerovate Therapeutics, Novartis, Keros Therapeutics, Vigonvita Life Sciences, Insmed Incorporated, Chugai Pharmaceutical, Merck Sharp & Dohme, Janssen Pharmaceutical, Actelion, Gossamer Bio, Lung Biotechnology PBC, United Therapeutics, Gilead Science, Acceleron Pharma, Eiger BioPharmaceuticals, AstraZeneca, and others

• Key Pulmonary Arterial Hypertension Therapies: AV-101, LTP001, KER-012, TPN171H, Treprostinil Palmitil, Satralizumab (Genetical Recombination), Sotatercept, Macitentan, ACT-293987, GB002 (seralutinib), Parenteral Treprostinil, Ralinepag, Selonsertib, Sotatercept, ubenimex, Olaparib, and others

• Pulmonary Arterial Hypertension Therapeutic Assessment: Pulmonary Arterial Hypertension current marketed and Pulmonary Arterial Hypertension emerging therapies

• Pulmonary Arterial Hypertension Market Dynamics: Pulmonary Arterial Hypertension market drivers and Pulmonary Arterial Hypertension market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Pulmonary Arterial Hypertension Unmet Needs, KOL’s views, Analyst’s views, Pulmonary Arterial Hypertension Market Access and Reimbursement

To know more about Pulmonary Arterial Hypertension companies working in the treatment market, visit @ Pulmonary Arterial Hypertension Clinical Trials and Therapeutic Assessment

Table of Contents

1. Pulmonary Arterial Hypertension Market Report Introduction

2. Executive Summary for Pulmonary Arterial Hypertension

3. SWOT analysis of Pulmonary Arterial Hypertension

4. Pulmonary Arterial Hypertension Patient Share (%) Overview at a Glance

5. Pulmonary Arterial Hypertension Market Overview at a Glance

6. Pulmonary Arterial Hypertension Disease Background and Overview

7. Pulmonary Arterial Hypertension Epidemiology and Patient Population

8. Country-Specific Patient Population of Pulmonary Arterial Hypertension

9. Pulmonary Arterial Hypertension Current Treatment and Medical Practices

10. Pulmonary Arterial Hypertension Unmet Needs

11. Pulmonary Arterial Hypertension Emerging Therapies

12. Pulmonary Arterial Hypertension Market Outlook

13. Country-Wise Pulmonary Arterial Hypertension Market Analysis (2020–2034)

14. Pulmonary Arterial Hypertension Market Access and Reimbursement of Therapies

15. Pulmonary Arterial Hypertension Market Drivers

16. Pulmonary Arterial Hypertension Market Barriers

17. Pulmonary Arterial Hypertension Appendix

18. Pulmonary Arterial Hypertension Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pulmonary Arterial Hypertension Market Set to Grow Substantially Through 2034, DelveInsight Projects | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros

DelveInsight’s “Prader-Willi Syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Prader-Willi Syndrome, historical and forecasted epidemiology as well as the Prader-Willi Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Prader-Willi Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Prader-Willi Syndrome pipeline products will significantly revolutionize the Prader-Willi Syndrome market dynamics.

To Know in detail about the Prader-Willi Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Prader-Willi Syndrome Market Forecast

Some of the key facts of the Prader-Willi Syndrome Market Report:

• The Prader-Willi Syndrome market size was valued ~USD 600 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In April 2025, Vykat XR featured an extended-release formulation of diazoxide choline, the crystalline salt form of diazoxide. While its precise mechanism of action remains uncertain, it is believed to reduce hyperphagia in individuals with Prader-Willi syndrome by activating ATP-sensitive potassium channels in the hypothalamus. The FDA approval was based on results from a 16-week, Phase 3, double-blind, placebo-controlled, randomized withdrawal trial (ClinicalTrials.gov Identifier: NCT03714373), which was preceded by an open-label treatment phase with diazoxide choline extended-release.

• In March 2025, The FDA approved Soleno Therapeutics’ diazoxide choline (DCCR) extended-release tablets, branded as Vykat XR, for managing hyperphagia in individuals aged 4 and older with Prader-Willi syndrome (PWS). This marks a significant milestone as Vykat XR becomes the first approved therapy specifically targeting hyperphagia in PWS. DCCR is a proprietary, once-daily extended-release formulation of diazoxide choline, the crystalline salt form of diazoxide, designed to address the excessive hunger characteristic of the condition.

• In March 2025, Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company focused on developing innovative treatments for rare diseases, has announced that the U.S. Food and Drug Administration (FDA) has approved VYKAT XR (diazoxide choline) extended-release tablets, formerly known as DCCR, for treating hyperphagia in adults and children aged 4 and older with Prader-Willi syndrome (PWS).

• The overall market size for PWS in the US was projected to be approximately USD 500 million in 2023, with expectations for growth throughout the forecast period (2024–2034).

• In EU4 and the UK, Germany held the largest market share, with a market size of approximately USD 30 million in 2023, and this is anticipated to increase during the forecast period (2024–2034).

• There is significant uncertainty regarding the therapies from Gedeon Richter and Palobiofarma due to a lack of substantial evidence on their safety and efficacy. In contrast, Palobiofarma’s PBF-999 is anticipated to be launched first in Spain.

• In 2023, the US had the highest number of prevalent cases of PWS among the 7MM, totaling approximately 22,600 cases, which are projected to rise during the forecast period.

• In 2023, Germany had the highest number of total prevalent cases of PWS among the EU4 and the UK, whereas Spain recorded the lowest number of cases.

• Estimates indicate that in Japan, PWS was most commonly seen in the 18-40 age group, representing over 38% of all cases in 2023.

• In 2023, within the United States, the paternal microdeletion subtype represented the largest share of genetic subtype-specific cases of PWS, comprising around 70% of cases, while the translocation subtype was the least prevalent.

• Key Prader-Willi Syndrome Companies: Novo Nordisk, Pfizer, Sandoz, Harmony Biosciences, Soleno Therapeutics, Harmony Biosciences, ACADIA Pharmaceuticals, Aardvark Therapeutics, Gedeon Richter, Palobiofarma, ConSynance Therapeutics, and others

• Key Prader-Willi Syndrome Therapies: NORDITROPIN, GENOTROPIN, OMNITROPE, WAKIX (pitolisant), Diazoxide Choline Controlled-Release (DCCR), WAKIX (pitolisant), DCCR (diazoxide choline), Carbetocin (LV-101), ARD-101, RGH-706, PBF-999, CSTI-500, and others

• The Prader-Willi Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Prader-Willi Syndrome pipeline products will significantly revolutionize the Prader-Willi Syndrome market dynamics.

Prader-Willi Syndrome Overview

Prader-Willi Syndrome (PWS) is a complex genetic disorder that affects many parts of the body. The condition is characterized by weak muscle tone (hypotonia) and feeding difficulties in infancy, followed by excessive eating and gradual development of obesity. Individuals with Prader-Willi Syndrome typically have intellectual disability, behavioral problems, and distinctive physical features such as almond-shaped eyes, a narrowing of the head at the temples, and a turned-down mouth.

Get a Free sample for the Prader-Willi Syndrome Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/prader-willi-syndrome-market

Prader-Willi Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Prader-Willi Syndrome Epidemiology Segmentation:

The Prader-Willi Syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Prader-Willi Syndrome

• Prevalent Cases of Prader-Willi Syndrome by severity

• Gender-specific Prevalence of Prader-Willi Syndrome

• Diagnosed Cases of Episodic and Chronic Prader-Willi Syndrome

Download the report to understand which factors are driving Prader-Willi Syndrome epidemiology trends @ Prader-Willi Syndrome Epidemiology Forecast

Prader-Willi Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Prader-Willi Syndrome market or expected to get launched during the study period. The analysis covers Prader-Willi Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Prader-Willi Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Prader-Willi Syndrome Therapies and Key Companies

• NORDITROPIN: Novo Nordisk

• GENOTROPIN: Pfizer

• OMNITROPE: Sandoz

• WAKIX (pitolisant): Harmony Biosciences

• Diazoxide Choline Controlled-Release (DCCR): Soleno Therapeutics

• WAKIX (pitolisant): Harmony Biosciences

• DCCR (diazoxide choline): Soleno Therapeutics

• Carbetocin (LV-101): ACADIA Pharmaceuticals

• ARD-101: Aardvark Therapeutics

• RGH-706: Gedeon Richter

• PBF-999: Palobiofarma

• CSTI-500: ConSynance Therapeutics

Discover more about therapies set to grab major Prader-Willi Syndrome market share @ Prader-Willi Syndrome Treatment Landscape

Scope of the Prader-Willi Syndrome Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Prader-Willi Syndrome Companies: Novo Nordisk, Pfizer, Sandoz, Harmony Biosciences, Soleno Therapeutics, Harmony Biosciences, ACADIA Pharmaceuticals, Aardvark Therapeutics, Gedeon Richter, Palobiofarma, ConSynance Therapeutics, and others

• Key Prader-Willi Syndrome Therapies: NORDITROPIN, GENOTROPIN, OMNITROPE, WAKIX (pitolisant), Diazoxide Choline Controlled-Release (DCCR), WAKIX (pitolisant), DCCR (diazoxide choline), Carbetocin (LV-101), ARD-101, RGH-706, PBF-999, CSTI-500, and others

• Prader-Willi Syndrome Therapeutic Assessment: Prader-Willi Syndrome current marketed and Prader-Willi Syndrome emerging therapies

• Prader-Willi Syndrome Market Dynamics: Prader-Willi Syndrome market drivers and Prader-Willi Syndrome market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Prader-Willi Syndrome Unmet Needs, KOL’s views, Analyst’s views, Prader-Willi Syndrome Market Access and Reimbursement

To know more about Prader-Willi Syndrome companies working in the treatment market, visit @ Prader-Willi Syndrome Clinical Trials and Therapeutic Assessment

Table of Contents

1. Prader-Willi Syndrome Market Report Introduction

2. Executive Summary for Prader-Willi Syndrome

3. SWOT analysis of Prader-Willi Syndrome

4. Prader-Willi Syndrome Patient Share (%) Overview at a Glance

5. Prader-Willi Syndrome Market Overview at a Glance

6. Prader-Willi Syndrome Disease Background and Overview

7. Prader-Willi Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Prader-Willi Syndrome

9. Prader-Willi Syndrome Current Treatment and Medical Practices

10. Prader-Willi Syndrome Unmet Needs

11. Prader-Willi Syndrome Emerging Therapies

12. Prader-Willi Syndrome Market Outlook

13. Country-Wise Prader-Willi Syndrome Market Analysis (2020–2034)

14. Prader-Willi Syndrome Market Access and Reimbursement of Therapies

15. Prader-Willi Syndrome Market Drivers

16. Prader-Willi Syndrome Market Barriers

17. Prader-Willi Syndrome Appendix

18. Prader-Willi Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Prader-Willi Syndrome Market Expected to Experience Major Growth by 2034, According to DelveInsight | Novo Nordisk, Pfizer, Sandoz, Harmony Biosciences, Soleno Therapeutics, Harmony Biosciences

DelveInsight’s “Peripheral Nerve Injuries Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Peripheral Nerve Injuries, historical and forecasted epidemiology as well as the Peripheral Nerve Injuries market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Peripheral Nerve Injuries market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Peripheral Nerve Injuries Market Forecast

Some of the key facts of the Peripheral Nerve Injuries Market Report:

• The Peripheral Nerve Injuries market size was valued approximately USD 2.4 billion in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In May 2025, A pioneering first-in-human study demonstrated the promise of the PeriPulse® Nerve Stimulation System—a wearable, temporary nerve stimulator—in delivering electrical stimulation therapy to support the regeneration of acutely injured peripheral nerves. Published in Bioelectronic Medicine, the study reported that 87.5% of patients receiving the treatment showed clinically meaningful improvements in sensation six months post-injury, compared to pre-surgery status. These findings suggest electrical stimulation may play a vital role in promoting functional nerve recovery. Peripheral nerve injury treatment remains a significant challenge, particularly in acute trauma, as surgery alone often leads to delayed and incomplete recovery, placing strain on patients and healthcare systems alike.

• In April 2025, TISSIUM, a privately held medtech company specializing in biomorphic programmable polymers for tissue reconstruction, announced clinical data presented at the IFSSH Congress in Washington, D.C. on March 27, 2025. The findings highlight the promise of its COAPTIUM® CONNECT System—an innovative, sutureless, and atraumatic approach for peripheral nerve repair. Peripheral nerve injuries continue to present a serious clinical challenge, often leading to compromised nerve function, diminished dexterity, and a decline in overall quality of life.

• In September 2024, Neuraptive Therapeutics Inc., a biopharmaceutical company specializing in innovative treatments for peripheral nerve injuries, has announced that interim topline findings from its ongoing Phase 2 NEUROFUSE Study will be shared at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting.

• In January 2024, The U.S. Food and Drug Administration (FDA) has recognized Neuraptive Therapeutics’ NTX-001 as a promising treatment for peripheral nerve injury. It first granted the therapy Fast Track Designation in May 2020, and subsequently awarded it Orphan Drug Designation.

• In 2023, the United States represented the largest market for peripheral nerve injury treatments within the 7MM, reaching a value of approximately USD 1.5 billion.

• The US had the highest prevalence of peripheral nerve injuries within the 7MM in 2023, with case numbers approaching 1.7 million.

• Within the EU4 (Germany, France, Italy, Spain) and the UK, Italy had the most peripheral nerve injury cases, with France second highest, and Spain reporting the fewest.

• In 2023, the United States saw a greater incidence of upper limb injuries, with nearly 1.2 million cases, compared to roughly 0.5 million cases of lower limb injuries.

• The United States led the 7MM in surgical procedures for peripheral nerve injuries in 2023, with approximately 770,000 surgeries performed.

• Key Peripheral Nerve Injuries Companies: Axogen Corporation, Toyobo, KLISBio, Orthocell Limited, Orthocell, Neuraptive Therapeutics, Samyang Biopharmaceuticals, Astellas Pharma Inc, and others

• Key Peripheral Nerve Injuries Therapies: Avance Nerve Graft, Nerbridge, SilkBridge, CelGro, Remplir, NTX-001, CAPNP, QUTENZA, and others

• The Peripheral Nerve Injuries epidemiology based on extremities-specific population analyzed that the epidemiological model estimates a higher proportion of upper extremities in Peripheral Nerve Injuries

• The Peripheral Nerve Injuries market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Peripheral Nerve Injuries pipeline products will significantly revolutionize the Peripheral Nerve Injuries market dynamics.

Peripheral Nerve Injuries Overview

The central nervous system—the brain and spinal cord—transmits information to every other organ of the body through the enormous communications network known as the peripheral nervous system (PNS). The brain and spinal cord are also provided with sensory information through peripheral nerves (PN), such as a message indicating that the feet are cold or a finger is burned.

Get a Free sample for the Peripheral Nerve Injuries Market Report

https://www.delveinsight.com/report-store/peripheral-nerve-injuries-market

Peripheral Nerve Injuries Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Peripheral Nerve Injuries Epidemiology Segmentation:

The Peripheral Nerve Injuries market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Peripheral Nerve Injuries

• Prevalent Cases of Peripheral Nerve Injuries by severity

• Gender-specific Prevalence of Peripheral Nerve Injuries

• Diagnosed Cases of Episodic and Chronic Peripheral Nerve Injuries

Download the report to understand which factors are driving Peripheral Nerve Injuries epidemiology trends @ Peripheral Nerve Injuries Epidemiology Forecast

Peripheral Nerve Injuries Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Peripheral Nerve Injuries market or expected to get launched during the study period. The analysis covers Peripheral Nerve Injuries market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Peripheral Nerve Injuries Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Peripheral Nerve Injuries Therapies and Key Companies

• Avance Nerve Graft: Axogen Corporation

• Nerbridge: Toyobo

• SilkBridge: KLISBio

• CelGro: Orthocell Limited

• Remplir: Orthocell

• NTX-001: Neuraptive Therapeutics

• CAPNP: Samyang Biopharmaceuticals

• QUTENZA: Astellas Pharma Inc

Discover more about therapies set to grab major Peripheral Nerve Injuries market share @ Peripheral Nerve Injuries Treatment Market

Peripheral Nerve Injuries Market Drivers

• High incidence of nerve injuries

• Availability of technologically advanced nerve repair and regeneration products

• Research and Development

Peripheral Nerve Injuries Market Barriers

• Delayed and under diagnosis

• Lack of epidemiological studies

• Limited understanding of the pathophysiology of Peripheral Nerve Injuries and repair

• Lack of approved therapies and weak clinical pipeline

Scope of the Peripheral Nerve Injuries Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Peripheral Nerve Injuries Companies: Axogen Corporation, Toyobo, KLISBio, Orthocell Limited, Orthocell, Neuraptive Therapeutics, Samyang Biopharmaceuticals, Astellas Pharma Inc, and others

• Key Peripheral Nerve Injuries Therapies: Avance Nerve Graft, Nerbridge, SilkBridge, CelGro, Remplir, NTX-001, CAPNP, QUTENZA, and others

• Peripheral Nerve Injuries Therapeutic Assessment: Peripheral Nerve Injuries current marketed and Peripheral Nerve Injuries emerging therapies

• Peripheral Nerve Injuries Market Dynamics: Peripheral Nerve Injuries market drivers and Peripheral Nerve Injuries market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Peripheral Nerve Injuries Unmet Needs, KOL’s views, Analyst’s views, Peripheral Nerve Injuries Market Access and Reimbursement

To know more about Peripheral Nerve Injuries companies working in the treatment market, visit @ Peripheral Nerve Injuries Clinical Trials and Therapeutic Assessment

Table of Contents

1. Peripheral Nerve Injuries Market Report Introduction

2. Executive Summary for Peripheral Nerve Injuries

3. SWOT analysis of Peripheral Nerve Injuries

4. Peripheral Nerve Injuries Patient Share (%) Overview at a Glance

5. Peripheral Nerve Injuries Market Overview at a Glance

6. Peripheral Nerve Injuries Disease Background and Overview

7. Peripheral Nerve Injuries Epidemiology and Patient Population

8. Country-Specific Patient Population of Peripheral Nerve Injuries

9. Peripheral Nerve Injuries Current Treatment and Medical Practices

10. Peripheral Nerve Injuries Unmet Needs

11. Peripheral Nerve Injuries Emerging Therapies

12. Peripheral Nerve Injuries Market Outlook

13. Country-Wise Peripheral Nerve Injuries Market Analysis (2020–2034)

14. Peripheral Nerve Injuries Market Access and Reimbursement of Therapies

15. Peripheral Nerve Injuries Market Drivers

16. Peripheral Nerve Injuries Market Barriers

17. Peripheral Nerve Injuries Appendix

18. Peripheral Nerve Injuries Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Peripheral Nerve Injuries Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Orthocell, Neuraptive Therapeutics, Samyang Biopharmaceuticals